125 related articles for article (PubMed ID: 16890274)
1. Clusterin confers paclitaxel resistance in cervical cancer.
Park DC; Yeo SG; Shin EY; Mok SC; Kim DH
Gynecol Oncol; 2006 Dec; 103(3):996-1000. PubMed ID: 16890274
[TBL] [Abstract][Full Text] [Related]
2. Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy.
Watari H; Ohta Y; Hassan MK; Xiong Y; Tanaka S; Sakuragi N
Gynecol Oncol; 2008 Mar; 108(3):527-32. PubMed ID: 18177691
[TBL] [Abstract][Full Text] [Related]
3. The novel serine protease tumor-associated differentially expressed gene-14 (KLK8/Neuropsin/Ovasin) is highly overexpressed in cervical cancer.
Cané S; Bignotti E; Bellone S; Palmieri M; De las Casas L; Roman JJ; Pecorelli S; Cannon MJ; O'brien T; Santin AD
Am J Obstet Gynecol; 2004 Jan; 190(1):60-6. PubMed ID: 14749636
[TBL] [Abstract][Full Text] [Related]
4. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of SKP2 and phospho-MAPK/ERK1/2 and decreased expression of p27 during tumor progression of cervical neoplasms.
Chen TP; Chen CM; Chang HW; Wang JS; Chang WC; Hsu SI; Cho CL
Gynecol Oncol; 2007 Mar; 104(3):516-23. PubMed ID: 17079005
[TBL] [Abstract][Full Text] [Related]
6. An association between clusterin over-expression and taxol-resistance in ovarian cancer.
Hassan MK
Hokkaido Igaku Zasshi; 2008 Sep; 83(5):335-46. PubMed ID: 18946958
[No Abstract] [Full Text] [Related]
7. Low expression of S100P associated with paclitaxel resistance in ovarian cancer cell line.
Gao JH; He ZJ; Wang Q; Li X; Li YX; Liu M; Zheng JH; Tang H
Chin Med J (Engl); 2008 Aug; 121(16):1563-8. PubMed ID: 18982869
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of matrix metalloproteinase-2 in cancer of uterine cervix: a semiquantitative study of immunoreactivities using tissue array.
Wang PH; Ko JL; Tsai HT; Yang SF; Han CP; Lin LY; Chen GD
Gynecol Oncol; 2008 Mar; 108(3):533-42. PubMed ID: 18177928
[TBL] [Abstract][Full Text] [Related]
9. Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia.
Lee KM; Cao D; Itami A; Pour PM; Hruban RH; Maitra A; Ouellette MM
Histopathology; 2007 Oct; 51(4):539-46. PubMed ID: 17714470
[TBL] [Abstract][Full Text] [Related]
10. Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells.
Yim EK; Tong SY; Ho EM; Bae JH; Um SJ; Park JS
Oncol Rep; 2009 Feb; 21(2):549-57. PubMed ID: 19148534
[TBL] [Abstract][Full Text] [Related]
11. Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro.
Mori T; Kinoshita Y; Watanabe A; Yamaguchi T; Hosokawa K; Honjo H
Cancer Chemother Pharmacol; 2006 Nov; 58(5):665-72. PubMed ID: 16534615
[TBL] [Abstract][Full Text] [Related]
12. GBP1 overexpression is associated with a paclitaxel resistance phenotype.
Duan Z; Foster R; Brakora KA; Yusuf RZ; Seiden MV
Cancer Chemother Pharmacol; 2006 Jan; 57(1):25-33. PubMed ID: 16028104
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of GRP94 protein is associated with decreased sensitivity to X-rays in cervical cancer cell lines.
Kubota H; Suzuki T; Lu J; Takahashi S; Sugita K; Sekiya S; Suzuki N
Int J Radiat Biol; 2005 Sep; 81(9):701-9. PubMed ID: 16368648
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
Zhou Y; Inaba S; Liu J
Int J Oncol; 2006 Jul; 29(1):289-95. PubMed ID: 16773211
[TBL] [Abstract][Full Text] [Related]
15. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
[TBL] [Abstract][Full Text] [Related]
16. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
[TBL] [Abstract][Full Text] [Related]
17. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
Duan Z; Foster R; Bell DA; Mahoney J; Wolak K; Vaidya A; Hampel C; Lee H; Seiden MV
Clin Cancer Res; 2006 Sep; 12(17):5055-63. PubMed ID: 16951221
[TBL] [Abstract][Full Text] [Related]
18. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
[TBL] [Abstract][Full Text] [Related]
19. Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer.
Song T; Jeon HK; Hong JE; Choi JJ; Kim TJ; Choi CH; Bae DS; Kim BG; Lee JW
Cancer Res Treat; 2017 Jul; 49(3):595-606. PubMed ID: 27669706
[TBL] [Abstract][Full Text] [Related]
20. Targeting megalin to enhance delivery of anti-clusterin small-interfering RNA nanomedicine to chemo-treated breast cancer.
Xue HY; Wong HL
Eur J Pharm Biopharm; 2012 May; 81(1):24-32. PubMed ID: 22369881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
